MARINOBUFAGENIN (MBG) IS THE most extensively studied of the bufodienolides, a group of circulating cardiotonic steroids (34 -36) . Along with their "cousins," the cardenolides, they comprise those agents referred to as the cardiac glycosides (Fig. 1 ). These two groups of compounds have in common their ability to inhibit the ubiquitous enzyme sodium/potassium adenosine triphosphatase (Na ϩ /K ϩ ATPase). Both the cardenolides and the bufodienolides are also alike in their physiological and pathophysiological effects: 1) they can cause vasoconstriction leading to hypertension; 2) they are cardiac inotropes; and 3) under normal circumstances, they are natriuretic (34 -36) . It has become increasingly clear over time that these agents may play an important role in the etiopathogenesis of those disorders in which volume expansion (10, 14, 15, 47) , ischemia (5, 11, 39, 44, 47) , tissue injury (8, 24, 34, 39, 43) , and hypoxia (4) occur. Following upon our thesis that elevated levels of MBG are important, if not the most important factor in the development of preeclampsia in a majority of cases, we examined the postulate that volume expansion (22) , leading to the excessive production of MBG (47) from early in pregnancy, sets the stage for much of the sequence of events leading to the disorder (33) . The volume expansion of the pregnant rat leads to hypertension, proteinuria, and intrauterine growth restriction (IUGR), the hallmarks of human preeclampsia (47) . MBG in the urine was elevated, prior to the development of the "preeclamptic" syndrome in these expanded animals (31, 46) . We then administered MBG to normal animals during early pregnancy and reproduced the "preeclamptic" syndrome (33, 47) . An important finding in human preeclampsia is evidence for vascular leak, as obtained from the examination of alterations in the hematocrit value (8, 33) . This alteration was also noted in our "preeclamptic rat" (33, 34) .
Finally, the antagonist of MBG developed in our laboratory, resibufogenin (RBG), has been demonstrated not only to prevent hypertension, proteinuria, and IUGR seen in our rat "preeclampsia" model, but also to prevent evidence of vascular leak (32) .
Previous studies from this laboratory have demonstrated that MBG is not only a biomarker, but it is pathogenetically involved in the pregnancy-specific disorder, preeclampsia, in an animal model of the syndrome (46) . Furthermore, the urinary and serum levels of MBG are also elevated in preeclamptic patients compared with those of women undergoing normal pregnancy (1, 3, 14, 27) . Additionally, it has been determined that MBG can cause hyperpermeability in postcapillary venules from the splanchnic circulation and in endothelial monolayers obtained from rat lung tissue (40, 42) .
The purpose of this study was to evaluate the "transcriptome" of MBG and the mechanism(s) by which it alters the permeability of the vascular endothelium. Preliminary observations have determined that these actions of MBG may be important in the changes that lead to cerebral edema in such disorders as eclampsia (40) and traumatic brain injury (34) . Therefore, in vitro investigations were pursued in endothelial monolayers derived from human brain tissue. Finally, we have examined the effects of MBG on the permeability of the endothelial monolayers, in an attempt to coordinate its vascular effects with its regulation of gene expression. These experimental observations provide the basis for this report.
MATERIALS AND METHODS
Cell culture. Early passage human brain microvascular endothelial cells (ScienCell, Carlsbad, CA) were grown in a fibronectin (10 g/ml)-coated T-75 flask with 10% FBS in endothelial cell medium. Confluent cells were detached from the flask after washing successively with PBS without Ca 2ϩ , Moscona's EDTA buffer, and 2ϫ trypsin. For permeability studies, Co-star Transwell membrane inserts (0.4-m pores; Sigma Aldrich) in a 24-well plate (insert area 0.33 cm 2 ) were precoated overnight with fibronectin (10 g/ml) in PBS solution. 30,000 human brain microvascular endothelial cells (HBMEC) were seeded on each insert and then grown for 5 days to allow the tight junctions to form. The integrity of the tight junctions was periodically tested for 5 days by adding FITC-BSA in control inserts and measuring the fluorescence in the lower chamber (40) . On the sixth day, increasing concentrations of MBG were added to triplicate wells, above and below the inserts bearing the cells. The cells were incubated for 6 h, following which FITC-BSA at a concentration of 5 mg/ml was added to the upper chamber of each well. After a 1-h incubation period, the medium from the lower chamber (abluminal) was harvested. The fluorescence of FITC-BSA (emission at 490 nm and excitation at 525 nm) was measured. A standard curve was generated to convert fluorescence values of the concentration of FITC-BSA. The permeability coefficient was calculated from the following equation:
where [A] is the abluminal concentration of FITC-BSA (mg/ml), t is time in seconds, A is the area of the membrane in cm 2 , V is the volume of the abluminal chamber (ml), and [L] is the luminal concentration.
To study altered gene expression in HBMEC, an effective dose of MBG (10 nM) was chosen. Twelve hours of treatment was selected to assess direct effects of MBG and allow time for mRNA concentrations to change. The cells were cultured in each of five 6-well plates (BD Biosciences, Franklin Lakes, NJ) in medium described above. Cells were incubated in a 5% CO 2 incubator at 37°C until they reached ϳ80% confluence. Cells were then serum-starved in medium containing 0.5% FBS for 24 h and washed twice with PBS; then medium containing 10% FBS was added. Three-well replicates were subsequently treated with either 10 nM MBG dissolved in DMSO or with DMSO only. Twelve hours later, cells were gently washed with PBS and frozen at Ϫ80°C in preparation for RNA extraction.
RNA isolation and complementary RNA labeling. Total cellular RNA was isolated with Tripure reagent (Roche, Indianapolis, IN) directly from the cells in each well. RNA concentrations in the individual samples were measured using a Nanodrop ND-1000 spectrophometer and assessed for quality on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Total RNA (200 ng) was combined with RNA Spike-In (Agilent Technologies) and labeled with Cy3 using the Low-Input Quick Amp kit, according to Agilent Technologies instructions. cRNA was purified on RNeasy Mini columns (Qiagen, Valencia, CA). Yield and specific labeling were determined using fluorospectrometry (NanoDrop ND-1000). More detailed protocols are provided in Ref. 25 .
Microarray hybridization, imaging, and analysis. Human Gene Expression microarrays (4 ϫ 44K v. 2, catalog G2519F, Agilent Technologies) were used. The hybridizations were performed with the gene expression hybridization kit (Agilent Technologies). After hybridization for 17 h at 65°C with rotation, microarrays were washed according to the Agilent one-color microarray protocol. The arrays were scanned at 5-m resolution on an Agilent Microarray Scanner (model 62505C). Scanning and image analysis were performed using the Agilent Microarray Scanner. Featured extraction software (version 9.5) was used for data extraction from raw microarray image files. Differentially expressed genes between breeds were identified on the basis of seasonality with GeneSpring GX (v. 10.0.2, Agilent) software. Calls were detected by employing the Agilent default flag settings for Agilent One-Color microarray analysis to identify "population outliers," "saturated," "not positive," "not uniform," and "not above background" spots. Normalization was performed as described previously (25) . Briefly, quantile normalization was applied to reduce variability between arrays. Array data were subjected to baseline normalization to the median expression level for each array. Minimum threshold was set to 1.0, and default quality control settings for expression signal strength and uniformity within software were utilized. Following baseline normalization and quality control, genes of interest were selected on the basis of relative expression differences. A cut-off of P Ͻ 0.05 and fold change 1.5-fold or higher between groups were used as the thresholds to generate lists of probes for subsequent analyses.
Quantitative PCR analyses. Quantitative RT-PCR (qRT-PCR) primers were designed for each gene product of interest using Primer Express 3.0 software (Applied Biosytems, Foster City, CA) and the sequence near the microarray probe (sequences in Table 2 ). Exceptions were ENKUR, GRIN2C, and ACER2 mRNAs. For those, the recommended TaqMan gene expression assay primer pairs and probes were purchased (Applied Biosystems; catalog numbers provided in Table 2 ). Samples of testes RNA (100 ng) were reverse transcribed with oligo-dT and random octamer primers and Superscript II (Invitrogen, Carlsbad, CA). qRT-PCR was performed in triplicate reactions with Power SYBR Green PCR Master Mix on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Dissociation curves indicated that the PCR products melted at the expected temperatures around 80°C. Three gene products [GAPDH, ribosomal protein large P0 (RPLP0), and peptidylprolyl isomerase (cyclophilin) A (PPIA)] were used for normalization. All three normalizing gene products had very good, low-stability values (all Ms Ͻ 0.05), far lower than the upper cutoff of 1.5 (45) . qRT-PCR quantities (2 Ϫ⌬Ct ) were normalized to GAPDH, RPLP0, and PPIA genes according to GeNorm (45) .
Statistics. Linear qRT-PCR values were analyzed by ANOVA (SAS, v. 9.1). Least squares means and standard errors are presented. The one-tailed Student's t-test was used to compare permeability values of treated vs. control HBMEC monolayers. The level of statistical significance was P Ͻ 0.05, unless otherwise noted.
RESULTS
MBG disrupts the integrity of the HBMEC cell monolayer, thus increasing permeability. MBG treatment disrupted the HBMEC monolayers grown to confluence on membrane inserts to enhance permeability to FITC-BSA (Fig. 2) . The 0 and 0.1 nM permeability coefficients did not differ from each other (P Ͼ 0.05). Coefficients for 1.0 nM, 10 nM, and 100 nM MBG differed significantly from both 0 and 0.1 nM (P Ͻ 0.05).
MBG regulates expression of VEGF receptor genes in HBMEC cells. The VEGFRs are produced from the FLT1 gene. The longest transcript produces a membrane VEGFR. A shorter transcript produces a soluble VEGFR (sFLT or FLTv2) that sequesters VEGF and prevents it from binding the membrane form. A mid-size transcript (FLTv3) also produces a soluble VEGFR, but the 3=UTR of the mRNA is severely truncated, implying different stability and regulation of that mRNA compared with the long FLT1 transcript. Since expression levels of both sFLT and FLTv3 mRNAs have been shown to be increased in preeclampsia (30) , their concentrations were investigated in HBMEC cells treated with 10 nM MBG for 12 h. MBG appeared to downregulate concentrations of both mRNAs in the HBMEC (Fig. 3) . However, only the 59% decrease in sFLT mRNA caused by MBG treatment was statistically significant (P Ͻ 0.05).
Microarray analysis identifies MBG-regulated genes in HBMEC cells. To discover the molecular mechanism of MBG action in endothelial cells and relate gene regulation to its effects on the permeability of their monolayers, the levels of 44,000 different transcripts were assessed in control and MBGtreated HBMEC cells by microarray analysis. The raw data sets are available at the Gene Expression Omnibus at NCBI (GSE51351). The normalized data were used to identify MBGregulated genes. There were 1,069 transcripts that were differentially expressed by 1.5-fold or more (P Ͻ 0.05; Table 2 ). MBG treatment upregulated concentrations of 737 transcripts and downregulated 333 others. From those, 12 gene products (six upregulated and six downregulated) were selected for analysis by qRT-PCR (Table 1) . Part of the basis for selection involved functional annotation of the differentially expressed genes from Table 2 with the Database for Annotation, Visualization, and Integrated Discovery, or DAVID, bioinformatics resources (21) . The majority of differentially expressed gene products participate in cell adhesion, including ADAM28, CLDN16, TMEM207, FERMT1, JAM2, and integrins ITGA2B and ITGB2. Although ESR1 mRNA hybridization signals did not meet quality criteria on the microarrays, ESR1 mRNA was added to the analyses because ESR1 protein and ESR2 protein (Table 1) are nuclear receptors that may bind MBG and act as liganddependent transcription factors.
Real-time RT-PCR quantifies differential expression of eight additional genes in HBMEC cells. Thirteen gene products (Table 1 and ESR1 mRNA) were selected from the larger set of MBG-regulated genes for qRT-PCR analyses of mRNA concentrations. Concentrations of ENKUR mRNA were confirmed as being upregulated by 57% by MBG treatment (Fig. 4) . Concentrations of seven mRNAs (ITGA2B, GRIN2C, FERMT1, SLC8A1, ESR1, CLDN16, and TMEM207) were downregulated by MBG treatment, with decreases ranging from 22 to 66%. Concentrations of the other five gene products analyzed by qRT-PCR (ACER2, ADAM28, JAM2, ITGB2, and ESR2 mRNAs) were not significantly regulated by MBG treatment (Fig. 5) . However, there was a trend (P ϭ 0.2) toward downregulation of ESR2 mRNA concentrations by 42%.
DISCUSSION
The rationale for our studies has been, and remains, a series of attempts to determine the bases for the preeclamptic disease process and its potential remedies. In the studies reported here, two aspects of the mechanisms of action of MBG were explored. First, we examined the ability of MBG to alter the permeability of endothelial monolayers obtained from the human brain. We found that MBG enhanced the permeability of HBMEC monolayers. These data are similar to previous results obtained in the studies focusing on vessels from the splanchnic circulation (44) and the examination of the effects of MBG applied in vitro on endothelial monolayers obtained from rat lung (41) .
We also examined the effects of MBG on gene expression in the HBMEC. Because VEGF is central to endothelial cell function in the blood-brain barrier (2), we examined the expression of two of its receptor transcripts: FLTv3 and sFLT. Both encode shortened receptor proteins that are soluble and sequester the VEGF to blunt its actions on cells. MBG treatment (10 nM for 12 h) downregulated the concentrations of sFLT mRNA by 59%. This finding is in contrast to the same dose of MBG upregulating sFLT protein levels by 50% in cytotrophoblast cells after 24 h of treatment (42) . In those cells derived from the placenta, the upregulation of sFLT protein was proposed as one way that MBG interfered with VEGF actions. In HBMEC, this mechanism of MBG action was not apparent.
To discover the global effects of MBG treatment on the transcriptome of HBMEC, microarray studies were performed. MBG regulated numerous gene products. When functional annotation was performed, the largest group of differentially expressed genes was involved in cell adhesion. This was expected, as a result of MBG's disruption of the integrity of the HBMEC monolayer. ENKUR mRNA was the only gene product confirmed by PCR, as being upregulated by MBG treatment in HBMEC. The ENKUR protein was recently identified for its interactions with calmodulin and transient receptor cation channel proteins (7) . Quantitative PCR also confirmed that MBG downregulated ITGA2B, GRIN2C, FERMT1, and TMEM207 genes in HBMEC, as was first identified on the microarrays. The ITGA2B gene encodes a cell surface receptor by which cells attach to fibronectin in extracellular matrix. The GRIN2C protein is a calcium channel that binds glutamate to open and drive an influx of calcium ions into cells. The protein product of the FERMT1 gene is involved with integrin signaling (and specifically that of ITGA2B) and attachment to the actin cytoskeleton (17) . Mutations of FERMT1 cause the Kindler syndrome in humans, an epidermolysis bullosa disease. Both the FERMT1 and TMEM207 proteins have roles in cancer cell invasion during metastasis, and upregulation of their genes indicates a poorer prognosis for patients in several types of cancer (23, 38) . MBG treatment also downregulated the ESR1 gene encoding estrogen receptor alpha in HBMEC. The identity of the receptor protein that binds MBG is currently under investigation.
Two gene products, SLC8A1 and CLDN16 mRNAs, which the microarray data indicated were upregulated by MBG, appeared to be downregulated when qRT-PCR quantified the concentrations of the mRNAs. This could be due to the normalization: microarrays were normalized across all hybridization signals, while the qRT-PCR used a normalization factor generated from only three genes. However, the three genes were quite stable over the data set and have been used by numerous other investigators for normalization (16, 49) . The disagreement between microarray and qRT-PCR data in the direction of regulation may also be due to the different regions of the mRNAs being bound by the microarray probe and being amplified by the PCR primers. An additional level of complexity comes from the eight different transcripts from the SLC8A1 gene, which could be differentially regulated. SLC8A1 (also known as NCX1) is a Na ϩ -Ca 2ϩ exchanger on the surface of cells that reduces intracellular Ca 2ϩ concentrations (26) . Preeclampsia is a disorder of pregnancy consisting in the development of new-onset hypertension and an abnormally elevated degree of protein excretion after the 20th wk of gestation (31) . The major concern in this illness is always the life of the mother and fetus. The progression of this disorder to eclampsia carries with it, as does the underlying process of preeclampsia, an alarming increase in the mortality rate and the significant possibility of long-term complications of surviving mothers and their progeny (18, 28, 31, 50) . Additionally, the welfare of the unborn child is at risk. Aside from morbidity and mortality issues, the most dreaded complication is the advent of IUGR. In this situation, stillbirth is a possibility, as are developmental abnormalities (6) . Furthermore, despite the very best care, including hospitalization of the newborn child in the neonatal intensive care unit, most often born prematurely, fatality of the child remains a possibility. Finally, both mother and child are at risk for the development of health complications in later life. These include an increased incidence of diabetes, hypertension, cardiovascular disease, and the development of chronic kidney disease (11, 46, 50) .
Studies of the actions of MBG have yielded the following information: elevated levels of MBG result from one or more of the following circumstances: 1) excessive volume expansion of the extracellular fluid compartment (during early pregnancy) (8, 9, 22, 31, 47) , 2) tissue injury (5, 8, 24, 33, 43) , 3) ischemia (10, 15, 33, 39) , and 4) hypoxia (4). A rat model of preeclampsia was developed by volume expanding normal pregnant animals (22, 47) . The method included replacing the animals' drinking water with saline and administering the mineralocorticoid desoxycorticosterone acetate (DOCA). The animals developed a syndrome resembling human preeclampsia, including hypertension, proteinuria, and IUGR (22) . A significant number of the pups of these "preeclamptic" animals were developmentally abnormal. The expansion of the extracellular fluid volume resulting in a "preeclamptic" syndrome in the rat model is confirmed by the human studies of Chesley (9) , who noted a reduced ability of preeclamptic patients to excrete sodium when challenged with intravenous hypertonic saline, compared with the ability of normal pregnant patients to do so.
The administration of MBG to normal pregnant animals from early pregnancy resulted in a syndrome identical to that described as initiated by DOCA and saline (22, 47) . When "preeclamptic" rats were studied by examining the vascular integrity of single postcapillary venules in the mesentery, using an in vivo technique, the preeclamptic rats demonstrated vascular leak when compared with vessels examined in nonpreg- nant (control) animals and normal pregnant rats (44) . Furthermore, the bolus injection of MBG into the circulation of normal rats resulted in the rapid disappearance of fluorescently labeled albumin from the vascular lumen. Finally, the imposition of cerebral injury in rats subjected to brain trauma induced by a contusion model of mild to moderate severity, resulted in a 2-to 3-fold increase in urinary MBG excretion compared with that of sham-operated animals (34) . In this model, the administration of an antagonist to MBG, resibufogenin (RBG), 1 h after the brain insult, greatly minimized the histologic effects of the trauma and caused the urinary MBG levels to return to values comparable to those obtained in sham animals (34) . The antagonistic effect of RBG to the actions of MBG was similar to that seen when RBG was administered from early pregnancy to animals destined to develop a syndrome resembling human PE (19) . That is, hypertension, abnormal proteinuria, and IUGR were prevented.
Intriguingly, ouabain (a molecule related to MBG) ( Fig. 1 ) regulates SLC8A1 protein levels in arterial myocytes. CLDN proteins are integral membrane proteins that interact within and between strands of tight junctions (20, 26) . CLDN16 can form cation-selective tight junctions. When CLDN16 was overexpressed with CLDN19 in LLC-PK epithelial cells, Na ϩ permeability increased (20) .
The molecular mechanisms by which MBG exerts its effects on monolayer permeability and gene expression are unknown. The data in the current report will serve as a basis for launching future studies. It is interesting that MBG downregulated CLDN16 and TMEM207 genes to a similar extent: by 63% and 66%, respectively. In addition, the CLDN16 and TMEM207 genes are extremely close to each other on human chromosome 3q28. For those two reasons, it appears that MBG coordinately regulates these two genes by a common mechanism (13) . Whether that mechanism will be common to the other MBGregulated genes remains to be elucidated. In any case, our understanding of how MBG acts on cells may lead to useful strategies for interventions in disease states, especially those with vascular leakage.
Perspectives and Significance
The studies reported in this article were prompted by earlier experiments involving studies performed in the pregnancyspecific disorder, preeclampsia. In an animal model of preeclampsia, we reproduced many of the findings of human preeclampsia, including evidence of vascular leak. The latter finding resulted in studies directed at determining the mechanism of this vascular abnormality. Previous studies from this laboratory provided evidence for the cause of the endothelial membrane abnormality pointing to involvement of the MAPK system with upregulation of apoptosis leading to dysfunction and disruption of the "tight-junction" proteins (41) .
In the current article, we detail our results, indicating the upregulation of several gene products and downregulation of others, several of which affected the mRNA of proteins involved in the maintenance of the integrity of endothelial membrane mRNA. These observations assist in the determination that the abnormal function of the endothelial membrane proteins may represent important causative mechanisms for vascular leak in preeclampsia. Furthermore, these findings provide the impetus for examining the role of MBG in these events not only in PE, but in other disorders manifesting vascular leakage. Additionally, they suggest the need to examine the efficacy of the antagonist of MBG, RBG, as a possible remedy. The latter study is currently under way.
